References
- Feinberg AP . The key role of epigenetics in human disease prevention and mitigation. N. Engl. J. Med.378(14), 1323–1334 (2018).
- Tordini F , AldinucciM , MilanesiL , LiòP , MerelliI. The genome conformation as an integrator of multi-omic data: the example of damage spreading in cancer. Front. Genet.7 (2016). http://journal.frontiersin.org/article/10.3389/fgene.2016.00194/full
- Jørgensen JT . Companion and complementary diagnostics: clinical and regulatory perspectives. Trends Cancer2(12), 706–712 (2016).
- Tsoneva DK , IvanovMN , ConevNV , ManevR , StoyanovDS , VinciguerraM. Circulating histones to detect and monitor the progression of cancer. Int. J. Mol. Sci.24(2), 942 (2023).
- Neel DS , BivonaTG. Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma. NPJ Precis. Oncol.1(1), 3 (2017).
- Lo YMD , CorbettaN , ChamberlainPFet al. Presence of fetal DNA in maternal plasma and serum. Lancet350(9076), 485–487 (1997).
- Allard WJ , TerstappenLWMM. CCR 20th anniversary commentary: paving the way for circulating tumor cells. Clin. Cancer Res.21(13), 2883–2885 (2015).
- Pantel K , Alix-PanabièresC. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol. Med.16(9), 398–406 (2010).
- Snyder MW , KircherM , HillAJ , DazaRM , ShendureJ. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell164(1–2), 57–68 (2016).
- Achour B , GosselinP , TerrierJet al. Liquid biopsy for patient characterization in cardiovascular disease: verification against markers of cytochrome P450 and P‐glycoprotein activities. Clin. Pharm. Ther.111(6), 1268–1277 (2022).
- Benincasa G , MansuetoG , NapoliC. Fluid-based assays and precision medicine of cardiovascular diseases: the ‘hope’ for Pandora’s box?J. Clin. Pathol.72(12), 785–799 (2019).
- Gaitsch H , FranklinRJM , ReichDS. Cell-free DNA-based liquid biopsies in neurology. Brain146(5), 1758–1774 (2023).
- Buzova D , MaugeriA , LiguoriAet al. Circulating histone signature of human lean metabolic-associated fatty liver disease (MAFLD). Clin. Epigenet.12(1), 126 (2020).
- Buzova D , BraghiniMR , BiancoSDet al. Profiling of cell‐free DNA methylation and histone signatures in pediatric NAFLD: a pilot study. Hepatol. Commun.6(12), 3311–3323 (2022).
- US FDA . List of cleared or approved companion diagnostic devices (in vitro and imaging tools) (2023). www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools
- Ltd Research and Markets . Companion diagnostics: technologies and markets (2023). www.researchandmarkets.com/reports/5416606/companion-diagnostics-technologies-and-markets
- Ltd Research and Markets . Global aspirin market–forecasts from 2022 to 2027 (2022). www.researchandmarkets.com/reports/5649095/global-aspirin-market-forecasts-from-2022-to
- Maliepaard M , NibiP , NibiG , PasmooijAMG. Evaluation of companion diagnostics in scientific advice and drug marketing authorization applications by the European Medicines Agency. Front. Med.9, 893028 (2022).
- Orellana García LP , EhmannF , HinesPA , RitzhauptA , BrandA. Biomarker and companion diagnostics–a review of medicinal products approved by the European Medicines Agency. Front. Med.8, 753187 (2021).
- EMA . Guidance on the procedural aspects for the consultation to the European Medicines Agency by a notified body on companion diagnostics (2022). www.ema.europa.eu/en/documents/scientific-guideline/guidance-procedural-aspects-consultation-european-medicines-agency-notified-body-companion_en.pdf.
- Agarwal A , SnyderG , ResslerD. The current and future state of companion diagnostics. PGPM8, 99–110 (2015).
- Tanaka A , SuzukiH , ToyoshimaS , NagaiN. Co-development of oncology drugs and companion diagnostics: analyses of approval lags and drug development periods in recently approved cases in Japan. Ther. Innov. Regul. Sci.56(1), 85–95 (2022).
- Fridlyand J , SimonRM , WalrathJCet al. Considerations for the successful co-development of targeted cancer therapies and companion diagnostics. Nat. Rev. Drug. Discov.12(10), 743–755 (2013).